3.1.10.8. belatacept. belatacept fusion protein, effectively blocks cd28 co-stimulatory pathway thereby prevents t-cell activation [279,347-350]. belatacept intravenously administered indicated use part cni-free regimen together basiliximab induction, mycophenolate, corticosteroids. long-term data three randomised studies de novo kidney transplant recipients demonstrated better renal function versus cyclosporine-based immunosuppression, although rates grades acute rejection higher belatacept first year post-transplant [243,246,259,279,349-355]. patients receiving standard deceased living donor kidney, better graft survival observed, similar graft survival rates found ecds. interestingly, belatacept-treated patients better preserved histology developed less donor specific antibodies (dsa) compared cyclosporine . long-term safety profile belatacept treated patients similar cyclosporine controls, less belatacept treated patients developed metabolic complications discontinued treatment due adverse events . addition, option converting patients (either stable patients due cni m-tor associated toxicity) explored promising initial results [347,348,352,357-359]. specific safety signals include higher rate post-transplant lymphoproliferative disorder (especially epstein-barr virus (ebv) negative patients), herpes infections, tuberculosis patients endemic areas [279,347-350]. belatacept approved u.s. europe ebv positive patients, yet available many countries. additional studies ongoing fully explore value compound. recommendationstrength ratingbelatacept may used immunosuppressive therapy immunologically low-risk patients, positive epstein-barr virus serology.weak